Quantcast

Latest Non-24-hour sleep-wake disorder Stories

2014-06-03 08:31:35

WASHINGTON, June 3, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ(TM) (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). "The EMA submission is an important milestone towards providing a treatment option for people living with Non-24 in the European Union," said Mihael...

2014-06-02 20:22:55

WASHINGTON, June 2, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) will present additional data from its HETLIOZ(TM) (tasimelteon) clinical development program at SLEEP 2014, the 28th Annual Meeting of Associated Professional Sleep Societies in Minneapolis, Minnesota. HETLIOZ(TM) data at SLEEP 2014 will be presented in one oral and six poster sessions. The data presentation schedule is as follows: Oral Presentation -- June 4(th) at 2:15 - 2:30pm, Assessment of...

2014-04-09 20:22:14

Vanda launches HETLIOZSolutions(TM), a patient resource for information and access to HETLIOZ(TM) WASHINGTON, April 9, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the availability of HETLIOZ(TM). HETLIOZ(TM) is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind.( )...

2014-02-28 08:25:02

The Non-24 Share More Campaign aims to educate totally blind people living with the disorder and their families through its health and wellness podcast series WASHINGTON, Feb. 28, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that it has partnered with Erik Weihenmayer, a world-renowned adventurer and the only blind person to climb Mount Everest, to support the Non-24 Share More Campaign and launch the expert podcast series available at...

2014-01-31 16:23:11

Non-24 is highly prevalent among the totally blind WASHINGTON, Jan. 31, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ(TM) (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ(TM) is the first FDA approved medication for Non-24. Non-24 was first described more than 60 years ago, and is a chronic, circadian rhythm disorder...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related